These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

797 related items for PubMed ID: 11858481

  • 1. Efficacy and safety of the factor VIII/von Willebrand factor concentrate, haemate-P/humate-P: ristocetin cofactor unit dosing in patients with von Willebrand disease.
    Lillicrap D, Poon MC, Walker I, Xie F, Schwartz BA, Association of Hemophilia Clinic Directors of Canada.
    Thromb Haemost; 2002 Feb; 87(2):224-30. PubMed ID: 11858481
    [Abstract] [Full Text] [Related]

  • 2. Safety and efficacy of continuous infusion of a combined factor VIII-von Willebrand factor (vWF) concentrate (Haemate-P) in patients with von Willebrand disease.
    Lubetsky A, Schulman S, Varon D, Martinowitz U, Kenet G, Gitel S, Inbal A.
    Thromb Haemost; 1999 Feb; 81(2):229-33. PubMed ID: 10063997
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Clinical efficacy and safety of the factor VIII/von Willebrand factor concentrate BIOSTATE in patients with von Willebrand's disease: a prospective multi-centre study.
    Dunkley S, Baker RI, Pidcock M, Price J, Seldon M, Smith M, Street A, Maher D, Barrese G, Stone C, Lloyd J.
    Haemophilia; 2010 Jul 01; 16(4):615-24. PubMed ID: 20331755
    [Abstract] [Full Text] [Related]

  • 6. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E, Windyga J, European Wilate Study Group.
    Haemophilia; 2009 Jan 01; 15(1):122-30. PubMed ID: 19149848
    [Abstract] [Full Text] [Related]

  • 7. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
    Budde U, Metzner HJ, Müller HG.
    Semin Thromb Hemost; 2006 Sep 01; 32(6):626-35. PubMed ID: 16977573
    [Abstract] [Full Text] [Related]

  • 8. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ, van Vliet HH, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, van der Velden A, Budde U.
    Clin Appl Thromb Hemost; 2007 Jan 01; 13(1):14-34. PubMed ID: 17164493
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Clinical efficacy in bleeding and surgery in von Willebrand patients treated with Fanhdi a highly purified, doubly inactivated FVIII/VWF concentrate.
    Hernandez-Navarro F, Quintana M, Jimenez-Yuste V, Alvarez MT, Fernandez-Morata R.
    Haemophilia; 2008 Sep 01; 14(5):963-7. PubMed ID: 18624696
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
    Michiels JJ, Gadisseur A, van der Planken M, Schroyens W, van de Velden A, Berneman Z.
    Semin Thromb Hemost; 2006 Sep 01; 32(6):636-45. PubMed ID: 16977574
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of highly purified, doubly virus-inactivated VWF/FVIII concentrates in inherited von Willebrand's disease: results of an Italian cohort study on 120 patients characterized by bleeding severity score.
    Federici AB, Barillari G, Zanon E, Mazzucconi MG, Musso R, Targhetta R, Mannucci PM.
    Haemophilia; 2010 Jan 01; 16(1):101-10. PubMed ID: 19811543
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A systematic overview of the first pasteurised VWF/FVIII medicinal product, Haemate P/ Humate -P: history and clinical performance.
    Berntorp E, Archey W, Auerswald G, Federici AB, Franchini M, Knaub S, Kreuz W, Lethagen S, Mannucci PM, Pollmann H, Scharrer I, Hoots K.
    Eur J Haematol Suppl; 2008 May 01; (70):3-35. PubMed ID: 18380871
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Successful treatment of urgent bleeding in von Willebrand disease with factor VIII/VWF concentrate (Humate-P): use of the ristocetin cofactor assay (VWF:RCo) to measure potency and to guide therapy.
    Gill JC, Ewenstein BM, Thompson AR, Mueller-Velten G, Schwartz BA, Humate-P Study Group.
    Haemophilia; 2003 Nov 01; 9(6):688-95. PubMed ID: 14750934
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of a new generation von Willebrand factor/factor VIII concentrate (Wilate®) in the management of perioperative haemostasis in von Willebrand disease patients undergoing surgery.
    Windyga J, von Depka-Prondzinski M, European Wilate® Study Group.
    Thromb Haemost; 2011 Jun 01; 105(6):1072-9. PubMed ID: 21437358
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.